Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer

  • Technology appraisal guidance
  • TA389
  • Published: 

Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222): appeal announcement

The Institute has received one appeal from PharmaMar.

The Appeal hearing took place at NICE, 10 Spring Gardens, London SW1A 2BU on Friday 24 April 2015 at 10am.

This page was last updated: 24 April 2015